Related Experiment Video

Updated: May 18, 2026

Bioluminescence Resonance Energy Transfer (BRET)-Based Assay for Measuring Interactions of CRAF with 14-3-3 Proteins in Live Cells
06:44

Bioluminescence Resonance Energy Transfer (BRET)-Based Assay for Measuring Interactions of CRAF with 14-3-3 Proteins in Live Cells

Published on: March 1, 2024

An adaptive Src-PDGFRA-Raf axis in rhabdomyosarcoma

Jinu Abraham1, Ying Xuan Chua, Jason M Glover

  • 1Pediatric Cancer Biology Program, Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, USA. abraham@ohsu.edu

Biochemical and Biophysical Research Communications
|September 11, 2012
PubMed

Insights

Targeting PDGFRA and Src family kinases (SFKs) overcomes resistance in alveolar rhabdomyosarcoma (aRMS). Combination therapy or Sorafenib effectively inhibits tumor growth by targeting the adaptive Src-Pdgfra-Raf-Mapk axis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Alveolar rhabdomyosarcoma (aRMS) is an aggressive pediatric cancer.
  • Initial treatment with PDGFRA inhibitors shows efficacy but acquired resistance is common.
  • Src family kinases (SFKs) have been identified as potential mediators of resistance.

Purpose of the Study:

  • To investigate the role of SFKs in PDGFRA inhibitor resistance in aRMS.
  • To evaluate combination therapy with PDGFRA and SFK inhibitors.
  • To assess the efficacy of Sorafenib, a multi-kinase inhibitor, in aRMS models.

Main Methods:

  • Utilized a murine aRMS model and primary cell cultures.
  • Compared resistant and untreated cell cultures to identify resistance mechanisms.
  • Tested combination therapy of PDGFRA and SFK inhibitors.
  • Evaluated Sorafenib treatment in vivo and in vitro for mouse and human aRMS cells.

Main Results:

  • SFKs potentiate PDGFRA signaling in resistant aRMS.
  • Combined PDGFRA and SFK inhibition demonstrated an additive effect on cell viability.
  • SFK inhibition alone had no effect in PDGFRA-deficient tumors.
  • Sorafenib effectively inhibited tumor growth in mouse models and human cell lines.

Conclusions:

  • An adaptive Src-Pdgfra-Raf-Mapk signaling axis is crucial for PDGFRA inhibition resistance in aRMS.
  • Targeting this axis with combination therapy or Sorafenib shows therapeutic potential.
  • Further investigation into this pathway could lead to improved aRMS treatment strategies.

More Related Videos

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...